SCHEDULE: Janus Henderson Amends Mirum Pharma Stake to 10%

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 10.0% beneficial ownership stake in Mirum Pharmaceuticals, Inc. common stock.

Summary

• Janus Henderson Group plc filed an Amendment No. 6 to Schedule 13G regarding its beneficial ownership in MIRUM PHARMACEUTICALS, INC.
• The reporting person, Janus Henderson Group plc, beneficially owns 4,997,586 shares of Mirum Pharmaceuticals' Common Stock.
• This ownership represents 10.0% of the class of securities.
• Janus Henderson Group plc holds shared voting power and shared dispositive power over all 4,997,586 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Janus Henderson Group plc is classified as an Investment Adviser (IA) and a Parent Holding Company (HC).
• JHIUS, JHIUKL, and JHIAIFML are identified as indirect subsidiaries of Janus Henderson, acting as registered investment advisers furnishing investment advice to Managed Portfolios.

Sentiment

Score: 7

Explanation: The filing indicates a significant 10.0% beneficial ownership by Janus Henderson Group plc in Mirum Pharmaceuticals, suggesting continued institutional confidence in the company. The statement that shares were acquired in the ordinary course of business and not for control purposes is a standard positive for stability.

Positives

• Janus Henderson Group plc maintains a significant 10.0% stake in Mirum Pharmaceuticals, indicating continued institutional investment interest.
• The acquisition and holding of shares are stated to be in the ordinary course of business, suggesting a long-term investment strategy rather than an attempt to influence control, which can be viewed as a sign of stability.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Mirum Pharmaceuticals' future outlook, as it is a disclosure of beneficial ownership by an institutional investor.

Management Comments

• "I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing highlights continued institutional investor interest in the pharmaceutical and biotechnology sector, specifically in Mirum Pharmaceuticals. A significant stake by a major asset manager like Janus Henderson can signal confidence in the company's market position and long-term prospects within its industry, potentially influencing other investors' perceptions.

Comparison to Industry Standards

• A 10.0% beneficial ownership stake by a large institutional investor such as Janus Henderson is a substantial holding, often interpreted as a strong vote of confidence in a company's strategic direction and market potential.
• This level of institutional investment is comparable to significant stakes held by asset managers in other mid-to-large cap pharmaceutical or biotech companies, where specialized funds frequently build considerable positions.
• For instance, similar institutional ownership percentages are observed in companies like BioMarin Pharmaceutical Inc. or Sarepta Therapeutics, Inc., where major investment firms hold significant portions of the outstanding shares, reflecting their long-term conviction.

Stakeholder Impact

• Shareholders: The continued significant stake by a major institutional investor like Janus Henderson could be viewed positively, potentially signaling confidence and stability in the company's stock.
• Management: While the filing states no intent to influence control, a large institutional holder can still exert influence through voting power on corporate matters.

Key Dates

Recommendation

Janus Henderson Group plc's disclosure of a 10.0% beneficial ownership in Mirum Pharmaceuticals, Inc. indicates a substantial and continued institutional investment. While this Schedule 13G filing does not provide operational or financial performance details, the significant stake by a reputable asset manager suggests a degree of confidence in the company's long-term prospects. Investors should monitor Mirum's operational performance and future disclosures, but this filing alone supports maintaining existing positions rather than initiating new ones or divesting.

Keywords

Janus Henderson Group, Mirum Pharmaceuticals, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Pharmaceuticals, Biotechnology